Abstract
The BrafV600E mutation has been detected in patients with metastatic melanoma, colon, thyroid, and other cancers. Studies suggested that tumors with this mutation are especially sensitive to BRAF inhibitors-hence the need to reliably determine the BRAF status of tumor specimens. The present technologies used to screen for this mutation fail to address the problems associated with infiltrating stromal and immune cells bearing wild-type BRAF alleles and thus may fail to detect the presence of mutant BRAFV600E tumors. We have developed a rapid, inexpensive method of BRAF analysis that reduces the contamination of wild-type BRAF sequences from tumor biopsies. The protocol involves a series of PCR amplifications and restriction digestions that take advantage of unique features of both wild-type and mutant BRAF RNA at codon 600. Using this protocol, mutant BRAF can be detected in RNA from mixed populations with as few as 0.1 % BRAFV600E mutant containing cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62:10–29
National Cancer Institute. Surveillance Epidemiology and End Results. http://seer.cancer.gov
Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526
Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819
Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714
Kefford R, Arkenau H, Brown MP, Millward M, et al (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28(15s):abstr 8503
Johannessen CM, Boehm JS, Kim SY et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968–972
Nazarian R, Shi H, Wang Q et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977
Montagut C, Sharma SV, Shioda T et al (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68:4853–4861
Poulikakos PI, Persaud Y, Janakiraman M et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 480:387–390
Shi H, Moriceau G, Kong X et al (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724
Villanueva J, Vultur A, Lee JT et al (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683–695
Kirkwood JM, Manola J, Ibrahim J et al (2004) A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:1670–1677
Gogas J, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709–718
Lin J, Goto Y, Murata H et al (2011) Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 104:464–468
Yancovitz M, Litterman A, Yoon J et al (2012) Intra- and inter-tumor heterogeneity of BRAFV600E mutations in primary and metastatic melanoma. PLoS One 7(1):e29336 (1–8)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Melanoma version 3 2012. (2012) http://www.nccn.org/professionals/physicians_gls/pdf/melanoma.pdf
Panka DJ, Sullivan RJ, Mier JW (2010) An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res 20:401–407
Mocellin S, Hoon D, Ambrosi A et al (2006) The prognostic value of circulating tumor cells in patients with melanoma: a systemic review and meta-analysis. Clin Cancer Res 12:4605–4613
Sullivan RJ, Lawrence DP, Flaherty KT et al (2012) Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay. J Clin Oncol 30(suppl; abstr 8516)
Kitago M, Koyanagi K, Nakamura T et al (2009) mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem 55:757–764
Langland R, Sharp T, Tsai J et al (2006) Development of a companion diagnostic test for inhibitors of V600E BRAF. First AACR international conference on molecular diagnostics in cancer therapeutic development, 12–15 Sept 2006, abstr A13
McCullough RM, Cantor CR, Ding C (2005) High-throughput alternative splicing quantification by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Nucleic Acids Res 33:e99
Elvidge GP, Price TS, Glenny L et al (2005) Development and evaluation of real competitive PCR for high-throughput quantitative applications. Anal Biochem 339:231–241
Kwak JY, Kim EK, Kim JK et al (2010) Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAF(V600E) mutation in FNAB samples of thyroid nodules in BRAF(V600E) mutation-prevalent area. Head Neck 32:490–498
Miller CJ, Cheung M, Sharma A et al (2004) Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 123:990–992
Board RE, Ellison G, Orr MC et al (2009) Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 101:1724–1730
Morlan J, Baker J, Sinicropi D (2009) Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One 4:e4584
Oldenburg RP, Liu MS, Kolodney MS (2008) Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA. J Invest Dermatol 128:398–402
Dominguez PL, Kolodney MS (2005) Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. Oncogene 24:6830–6834
Zatelli MC, Trasforini G, Leoni S et al (2009) BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 161:467–473
Domingo E, Laiho P, Ollikainen M et al (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41:664–668
Sidransky D, Cohen Y, Xing M (2008) BRAF mutation T1796A in thyroid cancers. US Patent 7,378,233, 27 May 2008
Oikonomou E, Makrodouli E, Evagelidou M et al (2009) BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia 11:1116–1131
French AJ, Sargent DJ, Burgart LJ et al (2008) Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14:3408–3415
Vandrovcova J, Lagerstedt-Robinsson K, Påhlman L et al (2006) Somatic BRAF-V600E mutations in familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 15:2270–2273
Cradic KW, Milosevic D, Rosenberg AM et al (2009) Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 94:5001–5009
Orru G, Coghe F, Faa G et al (2010) Rapid multiplex real-time PCR by molecular beacons for different BRAF allele detection in papillary thyroid carcinoma. Diagn Mol Pathol 19:1–8
Wojciechowska K, Lewinski A (2006) BRAF mutations in papillary thyroid carcinoma. Endocr Regul 40:129–138
Schiffman JD, Hodgson JG, VandenBerg SR et al (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70:512–519
Jeong JH, Wang Z, Guimaraes AS et al (2008) BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One 3:e3949
Litterman AJ, Pollens D, Warycha, MA et al (2008) Tumor heterogeneity: evidence from BRAF V600E mutation detection. J Clin Oncol 26(May 20 suppl;abstr 20022)
Ju ST, Panka DJ, Cui H et al (1995) Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444–448
Wilson BJ, Kocvara H (1975) A simple rapid method for layering blood on Ficoll-Isopaque gradients. J Immunol Methods 9:67–68
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Panka, D.J., Mier, J.W., Sullivan, R.J. (2014). Assaying for BRAF V600E in Tissue and Blood in Melanoma. In: Thurin, M., Marincola, F. (eds) Molecular Diagnostics for Melanoma. Methods in Molecular Biology, vol 1102. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-727-3_8
Download citation
DOI: https://doi.org/10.1007/978-1-62703-727-3_8
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-726-6
Online ISBN: 978-1-62703-727-3
eBook Packages: Springer Protocols